* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
The binding of receptors and ligands in living cells is a prerequisite for multiple biological reactions and is of great significance for most biological processes in organisms. BOC Sciences has extensive experience in ligand binding detection, and can use a variety of advanced technology platforms to provide technical services for measurement. We always ensure the accuracy and repeatability of the detection results and meet customer needs for high-quality, high-efficiency and low-cost technical services.
Proteolysis targeting chimera (Protac®) is composed of two ligands and a linker. The specificity of these two ligands allows Protac® to bind to the target protein and recruit E3 ubiquitin ligase. The binding of the ligand to the target protein determines whether Protac® can accurately locate the target protein, and the binding between the ligand and the E3 ubiquitin ligase is closely related to the ubiquitin cascade, and affects subsequent protein degradation reactions. Measurement of ligand binding is helpful for ligand design and screening, so it is necessary to detect and analyze the binding of two ligands during Protac® development or optimization.
BOC Sciences has a set of advanced technology platforms in the field of ligand binding assays, involving labeled ligand-binding assays, label-free ligand binding assays and whole cell ligand-binding assays. These assays include multiple techniques, such as fluorescence resonance energy transfer (FRET), surface plasmon resonance (SPR), SPR Imaging for affinity-based biosensors, surface acoustic wave biosensor, resonant waveguide grating (RWG) biosensor technologies, etc.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Please contact us with any specific requirements and we will get back to you as soon as possible.